Evidence map›Paper›PMID 38993666›Full record

ArticleiScience2024

A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity.

Erin Sellars, Margarita Savguira, Jie Wu, Sabrina Cancelliere, Mark Jen, Rehna Krishnan, Anne Hakem, Dalia Barsyte-Lovejoy, Razqallah Hakem, Steven A Narod and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erin SellarsDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Margarita SavguiraDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Jie WuDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Sabrina CancelliereDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Mark JenLunenfeld-Tanenbaum Research Institute, Network Biology Collaborative Centre, High-Throughput Screening, Mt. Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5, Canada.
Rehna KrishnanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Anne HakemPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Dalia Barsyte-LovejoyDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Razqallah HakemPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Steven A NarodWomen's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada.
Joanne KotsopoulosDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Leonardo SalmenaDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PARP inhibitors (PARPi) are efficacious in

Indexed as

CancerCell biologyPharmacology

Identifiers

PMID38993666
PMCPMC11238136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.